SAN DIEGO--(BUSINESS WIRE)--Nexus Dx Inc., founded in 2009 to consolidate technologies focused on point-of-care (POC) blood diagnostic testing, is pleased to announce the appointment of Joseph M. Nemmers, Jr. to the Company’s Board of Directors, effective immediately. Mr. Nemmers is the Principal in a private consulting practice specializing in the pharmaceutical and medical device industries, and serves as an advisor to Warburg Pincus LLC.
Mr. Nemmers previously served as Executive Vice President for Abbott Laboratories (NYSE:ABT), a global life science company with key lines of business in pharmaceutical, medical, diagnostic and nutritional products. He was responsible for five Abbott businesses, including the core laboratory, molecular and point-of-care diagnostics franchises, and directed the successful integration of Abbott’s $7 billion acquisition of Knoll Pharmaceuticals.
“We are excited to welcome Joe Nemmers, a seasoned professional in the high-growth diagnostics industry, to our board of directors,” said Nexus Dx President and CEO Jim Merselis. “He is an outstanding leader whose entrepreneurial approach, commercial insight and record of achievement in business integration will strengthen our capabilities and enable Nexus Dx to move to the next level of corporate growth and performance.”
Mr. Nemmers is currently a member of the board of directors of Advocate Condell Medical Center and Charitable Foundation. His past community-based board service includes being a member of The Shedd Aquarium board of trustees and Board Chair of the United Way of Lake County. He is also a former Commissioned Officer in the United States Army Reserve where he served for 13 years.
About Nexus Dx
Nexus Dx was formed in 2009 by Bay City Capital to take advantage of current and emerging market opportunities in POC diagnostics by consolidating products and technologies to create a company dedicated to improving patient outcomes and healthcare economics via decentralized blood diagnostic testing. In November 2010, the Company and International Technidyne Corporation, a global leader in the fields of hemostasis management and POC testing, were acquired by Warburg Pincus and merged into the current Nexus Dx organization. This transaction is the latest success in the aggressive roll-up model established by the Company’s executive team.
Nexus Dx is led by President and CEO Jim Merselis, who has more than 30 years of experience in the healthcare industry. He previously was CEO of HemoSense, Inc. (AMEX: HEM), which was sold in November 2007 to Inverness Medical Innovations (now Alere) for $265 million. Nexus Dx is backed by an investor syndicate consisting of Bay City Capital, Kleiner Perkins Caufield & Byers, Prolog Ventures and Warburg Pincus. For more information, please visit http://www.nexus-dx.com.